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Introduction
Initial therapy for patients with low-grade endometrial
satromal sarcoma (LESS) is surgery. Approximately 50%
of them develop recurrent disease, mainly in the pelvis or
the lung [1]. There is no standard therapy for cases of
recurrence, although chemotherapy is commonly used,
but unfortunately well-defined protocols are inexistent.
We describe the case of the third, consecutive, abdominal
recurrence of disease in the shape of huge polycystic
tumors, 10 years after primary treatment.
Case 
A 55-year-old woman with recurrence of LESS in the
shape of huge abdominal tumors was admitted to the
Gynecological Oncology Department of the Maria
Sklodowska-Curie Memorial Cancer Center and Institute
of Oncology in September 2004. In July 1994, after the
appearance of irregular bleeding, D&C was performed
and endometrial stromal sarcoma (LESS) was recognized.
She was operated and total abdominal hysterectomy with
bilateral salpingo-oophorectomy was performed. The
histopathological findings confirmed LESS. In August
1994 she underwent radiotherapy. External irradiation
was delivered to the pelvis with 18 MeV photons with
total dose 46 Gy. 
After 53 months of disease free survival, in February
1999, three cystic tumors: 50, 100, 110 mm in diameter, in
pelvis were found. She was operated again and the tumors
and infiltrated omentum were totally removed.
Pathological exam recognized metastatic LESS. After
that, there was no adjuvant therapy. Between March and
July 2000, due to pulmonary metastases, recognized by
a chest CT scan, she was given six cycles of chemotherapy
CAP (cisplatin, doxorubicine, cyclophosphamide) with
complete radiological remission .
In July 2001 consecutive recurrence was recognized
(by CT scan) in the shape of two, pelvic and abdominal
tumors 80 and 60 mm in diameter. She started second-
line chemotherapy (cisplatin, doxorubicine). After three
cycles, due to progression, chemotherapy was terminated.
Palliative care with Tamoxifen 20 mg and Megestrol 160
mg a day was introduced. Thereafter, increasing ascites
was periodically observed. Several times we performed
abdominal paracentesis, evacuating from 3000 to 6000
ml of ascites. In time, despite repeated paracenteses,
abdominal circumference remained increased. When the
symptoms of ileus and respiratory disturbances with
dyspnea occurred, we decided to operate her.
In September 2004, after 4 days of parenteral
nutrition and a transfucion of 600 ml of packed red cells,
explorative laparotomy was performed. We found two
cystic, multilocular tumors: the first one was 20 cm in
diameter and weighed 4 kg; it was situated under the
greater curvature of the stomach and transverse colon,
over the pancreas. The second one was located in the
middle part of the abdominal cavity and pelvis. It was 35
cm in diameter and weighed 12 kg. (Figure 1) The
polycystic tumor was accreted with the abdominal wall,
the small bowel, the colon and the mesosigmoid. We
found a lot of link vessels between tumor and abdominal
wall. Injury of these vessels caused massive bleeding.
Hemostasis was secured with hot gauze packs com-
pression or local coagulation. She underwent recto-
sigmoid resection en block with the tumor, and stapled
side-to-side anastomosis. The smaller tumor was sepa-
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rated from the stomach and the transverse colon and
removed as a whole. After that, there was no macroscopic
pathological mass in abdominal cavity. The overall blood
loss was 1200 ml and she required transfusion of 2 units
packed red cells and 600 ml of fresh-frozen plasma. There
were no complications during the postoperative period
and parenteral nutrition was continued for 5 days. Final
postoperative histopathology report confirmed LESS with
one mitosis per 20 high-power fields and moderate
nuclear pleomorphism (Figure 2). Immunohistochemical
study analyzed the following antigens: estrogen receptor
(ER), progesterone receptor (PR), smooth muscle anti-
gen (SMA), low molecular weight cytokeratin (CMA5.2),
MIB1, CD117 (c-kit) and CD34. 
ER was noted in 30% of cells. PR was absent. We
noted strong positive reaction with CAM5.2 and SMA. In
30% of the cells, the CD117 (c-kit) was expressed. There
was no expression of MIB1 and CD34 in all the cells
(Figures 3 and 4).
Now, eleven months after debulking, she is in
complete clinical and radiological (abdominal and pelvic
CT scan) remission. Her quality of life is good and all
respiratory disturbances have disappeared.
Discussion
Uterine sarcomas are aggressive gynecological malignan-
cies even at an early stage of disease. The most common
histological types are represented by leiomyosarcoma,
endometrial stromal sarcoma (ESS), and mixed mullerian
tumors. Estimated 5-year overall survival rate for all types
of tumors is 62%. ESS is characterized by proliferations
composed of cells with endometrial stromal cell differen-
tiation. A breakpoint of 10 mitoses per 10 high-power
fields is used to distinguish between low-grade and high-
grade endometrial stromal sarcoma and to evaluate the
prognostic value of mitotic count in patients with ESS
[2]. All authors agree, that LESS has the best prognosis of
these tumors. In the Royal Marsden Hospital study Livi et
al. estimated that 3-years survival rate was 63% in patients
with LESS. It was significantly related to stage, grade
and histological type [3]. 
Immunohistochemical analysis can provide some
prognostic information regarding LESS in early stages.
Geller et al., have described the outcomes and patterns of
failure in 28 patients with ESS (19 LESS and 9 HESS)
diagnosed over 31 years and the relationship to proto-
oncogene c-kit expression (CD 117). Positive tumors had
more than 10% of cells comprising the neoplasm display
22
Figure 1. The larger tumor (12 kg) after resection
Figure 3. Positive CAM5.2 immunohistochemical staining Figure 4. 30% positive CD117 (c-kit) immunohistochemical staining
Figure 2. LESS hematoxiline-eosine staining
immunoreactivity. The median survival of patients with c-
kit-positive versus c-kit-negative tumors was 12 and 47
months, respectively [4]. Our patient was c-kit-positive
in 30% of the cells.
Bhargava et al. studied soft-tissue neoplasm
including 17 ESS. Immunohistochemically, detecting the
following antigens: CD10, ER, PR, bcl-2, CD34, SMA,
epithelial membrane antigen and cytokeratin (AE1/AE3).
Most ESS stained positively for CD10 (16/17), ER
(17/17), PR (15/17), and bcl-2 (17/17). Staining with SMA
was seen in 11 of 17 cases of ESS, with more intense
staining seen in areas showing smooth muscle differen-
tiation. Staining with AE1/3 was seen in four of 17 ESS,
with two of the positive cases containing epithelioid cells.
None of the ESS expressed epithelial membrane antigen
or CD34. Differences between ESS and other soft-tissue
tumors were detected for all of the immunohistochemical
markers (P<0.05), except anti-bcl-2 and AE1/3 [5]. In
our case of LEES we fined ER in 30% of the cells and no
PR expression. None of the cells expressed CD34. In
addition we noted strong positive reaction with SMA and
CAM5.2. Humble et al. described CAM5.2 positive
reaction in all examined epithelioid sarcomas in different
localization [6].
Optimal primary treatment of early stages of disease
is total hysterectomy with bilateral salpingo-oopho-
rectomy. Unfortunately, it is not clear whether adjuvant
therapy improves prognosis. In the Royal Marsden
Hospital group, adjuvant radiotherapy with doses higher
than 50 Gy, decreased the local recurrence rate, but did
not have a significant impact on survival[3]. Our patient,
after postoperative radiotherapy with a dose 46 Gy, had
disease-free period of 53 months. Adjuvant chemotherapy
may form an approach, since distant recurrences are more
frequent than local failures. Unfortunately, there are
no standard programs for the treatment of recurrent
disease. The regimen of adjuvant chemotherapy currently
used in the treatment of uterine sarcomas is based on
ifosfamid and doxorubicin. There are some papers about
CYVADIC as adjuvant treatment in stage I uterine
sarcomas. Odunsi et al. have examined the efficacy and
results of long-term follow-up of 24 valuable patients with
completely staged uterine sarcomas. They received
adjuvant multiagent chemotherapy with vincristine,
doxorubicin, cyclophosphamide and dacarbazine for
a total of nine monthly cycles or until recurrence of
disease was documented. Overall, the patients received
206 of the planned 216 cycles of chemotherapy. The
median follow-up of the patient population was 93
months (range 11-213 months). Eight patients (33%)
developed recurrent disease. The median time to
recurrence was 19 months (range 7-184 months) [7]. Wall
and Starkhammar have described the effect of palliative
chemotherapy on soft tissue sarcomas given outside
controlled trials. Thirty-six patients were treated with
first-line chemotherapy CYVADIC, with a response rate
of 28% (median response duration 5.5 months). Eto-
poside and ifosfamide (includes granulocyte colony-
stimulating factor (G-CSF)) were used in the treatment of
18 patients. The response rate was 22% (median response
duration 4.5 months); Nineteen patients were treated
with doxorubicin+ifosfamide and one patient responded.
Four patients received other first-line treatments. Thirty-
eight patients were given second-line chemotherapy and 4
(10%) patients responded. Thirteen patients were given
third-line treatment and 5 patients received fourth-line
treatment, but without any response. Disease progression
was the dominant reason for discontinuation of therapy.
The authors have concluded that the treatment with
CYVADIC yields at least as high a response rate as the
more recently described doxorubicin + ifosfamide
combination, but third- and fourth-line therapy is not
beneficial [8].
After second recurrence with pulmonary metastases
our patient underwent six cycles of chemotherapy
consisted of cisplatin 100 mg, doxorubicin 100 mg,
cyclophosphamide 1000 mg with complete radiological
remission. 
Both lung and pelvis metastases are the main points
of LESS relapse, approximately in 50% of patients after
first line of therapy. However, there are rare cases, like
those described by Matsuura et al., of multiple bone and
lung recurrence in a patient with LESS. Metastases in
thoracic spine, ribs, iliac bone and sacrum area were
treated with external beam irradiation. It was effective
as a form of pain relief, although the size of the recurrent
tumor remained unchanged [1]. 
LESS, especially in its early stage, has the best
prognosis of all uterine sarcomas. Even in cases of
recurrent disease, overall survival may be long. Second
line therapy and further therapy are reasonable, although
the choice of the treatment method is difficult. Some-
times, during a consecutive relapse, surgery is only way of
therapy to save the patient’s life. We suggest that it should
be performed safety, but radically, whenever possible.
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